Table 2.
Anti-Angiogenics-Based | Anti-CTLA-4-Based | ||
---|---|---|---|
Bevacizumab-Based | TKIs-Based | ||
Strong criteria of choice | Pre-existing untreated auto-immune disorder (psoriasis…) | Severe vascular comorbidities Significant Portal Hypertension |
|
Criteria of choice subject to interpretation | Better toxicity profile | Non-severe vascular comorbidities Equilibrated arterial hypertension |
|
Low-risk auto-immune disorder (diabetes, thyroid disorder…) |